Developing an Erythromycin Ophthalmic Ointment: Putting the Puzzle Pieces Together
Download in electronic PDF format for $75
Abstract: With the development of new treatment options and reported side effects with the use of silver nitrate ophthalmic solution, the drug manufacturers discontinued production of the silver nitrate ophthalmic solution in the mid 1990s. On December 9, 2009, the U.S. Food and Drug Administration announced that the erythromycin ophthalmic ointment 1-gram tubes were commercially available again and production by the manufacturer was expected to meet the historical demands. Hospitals could expect to replenish their inventory reserves after the first quarter of 2010. However, manufacturer backorders have been increasing due to a variety of factors. If a hospital has a compounding laboratory, it is possible to prepare erythromycin ophthalmic ointment according to the United States Pharmacopeia Chapter <797> standards. Since the commercial product has been available for decades without any major shortages until 2009, there isn’t any published compounding information on how to prepare the ointment. This article discusses t
Related Keywords:
gonococcal ophthalmia neonatorum, neonatal blindness, newborns, erythromycin ophthalmic ointment, prophylaxis, drug shortage, treatment alternatives, topical antibiotic, intraocular antimicrobial, ocular administration, eye infection, formulation
Related Categories:
FORMULATIONS, OPHTHALMICS, PEDIATRICS, STERILE PREPARATIONS, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Developing an Erythromycin Ophthalmic Ointment: Putting the Puzzle Pieces Together
McElhiney Linda F
|
Jul/Aug 2010
Pg. 270-274
|
Compounding for the Effects of Weapons of Mass Destruction
Sammarco Domenic A
|
Jan/Feb 2003
Pg. 10-15
View Sample |
Erythromycin 1% and Neomycin Sulfate Ointment
Allen Loyd V Jr
|
Mar/Apr 2008
Pg. 153
|
Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Allen Loyd V Jr
|
Nov/Dec 2016
Pg. 495-500
|
Dexamethasone 0.1%, Neomycin 0.35%, and Polymixin 10,000 Units/g Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 2016
Pg. 228
|
Erythromycin 50-mg/mL Injection
Allen Loyd V Jr
|
Jan/Feb 2015
Pg. 64
|
Dexamethasone, Neomycin, and Polymyxin Ophthalmic Ointment
Allen Loyd V Jr
|
Jan/Feb 2016
Pg. 51
|
Tetracycline HCl 1% Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 2001
Pg. 212
|
Erythromycin and Dexamethasone Ophthalmic Solution
Allen Loyd V Jr
|
Nov/Dec 2002
Pg. 452
|
Dexamethasone Phosphate 0.05% Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 2003
Pg. 215
|
Bacitracin 500-U/g Ophthalmic Ointment
Allen Loyd V Jr
|
Nov/Dec 2003
Pg. 467
|
Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution
Allen Loyd V Jr
|
Sep/Oct 2010
Pg. 421
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Ointment Vehicles, Featured Excipient:
Allen Loyd V Jr
|
Mar/Apr 2001
Pg. 145-146
|
Glucose 40% Ophthalmic Ointment
Allen Loyd V Jr
|
May/Jun 1998
Pg. 230
|
Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 399-404
|
Chloramphenicol 1% Topical Ointment
Allen Loyd V Jr
|
Sep/Oct 2003
Pg. 373
|
Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution
|
Jan/Feb 2025
Pg. 51
|
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Jul/Aug 2021
Pg. 344-351
|
Return to Top |